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ABSTRACT 1 
Aims: The role of microvascular complications in the risk conferred by diabetes in heart failure 2 
with reduced ejection fraction (HFrEF) is unknown. 3 
Methods and results: We studied 2707 HFrEF patients in the Beta-blocker Evaluation of Survival 4 
Trial (BEST), stratified into 3 groups: no diabetes and diabetes without or with microvascular 5 
complications (neuropathy, nephropathy or retinopathy). The risks of the composite of 6 
cardiovascular death or heart failure hospitalization, and all-cause death, were studied using Cox 7 
regression analyses adjusted for other prognostic variables. 964 patients had diabetes, of which 313 8 
(32%) had microvascular complications. Patients with microvascular complications had more 9 
severe symptoms (New York Heart Association class IV 12% vs. 9% diabetes with no 10 
complications and 7% no diabetes), and worse quality of life (Minnesota living with HF median 11 
score 60 vs. 54 and 51 points). In patients with diabetes and complications, the rate of the composite 12 
outcome was 45 per 100 person-years of follow-up (compared with 34 and 29 in those with diabetes 13 
and no microvascular complications and participants without diabetes, respectively). Compared to 14 
patients without diabetes, the adjusted hazard ratio (HR) for the composite outcome was 1.44 (95% 15 
CI 1.22-1.70) and 1.18 (1.03-1.35) for patients with diabetes with and without complications, 16 
respectively. The risk of all-cause mortality was similarly elevated: adjusted HR 1.42 (95% CI 1.16-17 
1.74) and 1.20 (1.01-1.42), respectively.   18 
Conclusion: In HFrEF, diabetes with microvascular complications is associated with worse 19 
symptoms and outcomes, than diabetes without microvascular complications. Prevention of 20 
microvascular complications has the potential to improve HFrEF outcomes. 21 
Keywords: heart failure, diabetes, microvascular complications 22 
Clinical Trial Registration: URL http://www.clinicaltrials.gov. Unique identifier NCT00000560  23 
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INTRODUCTION 1 
It is well known that many patients with heart failure have a concomitant diagnosis of type 2 2 
diabetes and many additional patients have pre-diabetic dysglycemia.1-3 Heart failure patients with 3 
diabetes or pre-diabetic dysglycemia have worse clinical outcomes that those observed in patients 4 
with normal glycated hemoglobin.1-3 How diabetes and dysglycemia confer an excess risk in heart 5 
failure is uncertain. In individuals with diabetes, but without heart failure, microvascular disease, 6 
manifest as retinopathy, neuropathy and nephropathy, is strongly associated with adverse clinical 7 
outcomes. Furthermore, in these individuals, more microvascular complications are associated with 8 
greater risk.4-6 By contrast, the role of microvascular complications in the detrimental consequences 9 
of diabetes in heart failure with reduced ejection fraction (HFrEF) is unknown. We have 10 
investigated this question further in the Beta-blocker Evaluation of Survival Trial (BEST). 11 
 12 
 13 
METHODS 14 
BEST was a double-blind, placebo-controlled, randomized trial funded by the National Heart, Lung, 15 
and Blood Institute and the Department of Veterans Affairs. The design and results are published.7-9  16 
The trial was approved by the ethics committee at each study center, and all patients provided written 17 
informed consent. We used the de-identified public-use copy of BEST which included all but one 18 
participant, in the present analysis available at https://biolincc.nhlbi.nih.gov/studies/best/ upon 19 
application. 20 
. 21 
Study Patients: Briefly, 2708 patients assessed to be in New York Heart Association (NYHA) 22 
functional class III, or IV and with a left ventricular ejection fraction (LVEF) ≤35%, were enrolled 23 
in the United States and Canada between 1995 and 1998, and randomly assigned to receive 24 
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bucindolol or placebo. They were required to be on optimal medical therapy including the use of 1 
angiotensin-converting enzyme inhibitor therapy and before the publication of the Digitalis 2 
Investigation Group trial, digoxin was also required but afterwards it became discretionary.10 Key 3 
exclusion criteria included reversible causes of HFrEF, uncorrected primary valve disease, 4 
obstructive or hypertrophic cardiomyopathy, amyloidosis, myocarditis or a history of myocardial 5 
infarction within the previous six months.  6 
Diabetes and complications of diabetes: In BEST, information about diabetes and the complications of 7 
diabetes was collected by means of questions on the trial case report form. Regarding diagnosis, the 8 
question was “Does the patient have a documented history of diabetes at baseline (prior to 9 
randomization)?” Investigators were asked about microvascular complications as follows: “Does the 10 
patient have documented diabetic end organ disease at baseline (prior to randomization)?” If answered 11 
yes, there were additional questions (yes/no answers) about retinopathy, nephropathy and neuropathy.  12 
In the present analyses, we further defined “macrovascular” complications of diabetes as either 13 
evidence of coronary artery disease (prior myocardial infarction; prior coronary artery bypass grafting, 14 
prior coronary angioplasty; greater than 70% stenosis with corresponding wall motion abnormality, by 15 
coronary angiography; symptoms of angina; a positive stress perfusion study or a positive exercise test 16 
with interpretable baseline ECG) or peripheral artery disease. History of stroke/cerebrovascular disease 17 
was not collected in BEST.   18 
We divided patients with diabetes according to the presence of microvascular complications and for 19 
sensitivity analyses further into 4 groups according to the presence or absence of macrovascular 20 
complications. Additionally. we compared the impact of each microvascular complication separately as 21 
well as the risk associated with having more than one microvascular complication, and we repeated 22 
analyses without African-American patients. 23 
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Outcomes: The primary outcome in BEST was all-cause death but in the present manuscript we also 1 
examined the composite of cardiovascular death or heart failure hospitalization and each of its 2 
components, which were pre-specified secondary endpoints in the trial. 3 
Statistics: Baseline characteristics are presented as means with standard deviations for continuous 4 
variables and frequencies and percentages for categorical variables. Unadjusted event rates are reported 5 
per 100 patient years of follow-up according to diabetes status and the presence of microvascular 6 
complications. Cox proportional hazard models were applied to calculate hazard ratios (HR) and 7 
cumulative event curves according to diabetes status. The adjusted Cox regression models included 8 
information on age, sex, treatment, race (Caucasian vs. all other), systolic blood pressure, NYHA class, 9 
LVEF, heart rate, body mass index, estimated glomerular filtration rate (eGFR), heart failure duration, 10 
ischemic etiology, history of hypertension, atrial fibrillation and presence of a pacemaker or implanted 11 
cardioverter defibrillator. Log (-log(survival)) curves were used to evaluate the proportional hazard 12 
assumption.  The assumption of linearity of continuous variables (age) were tested by including a 13 
variable of age squared. All p values are two-sided, and a p value of <0.05 was considered significant. 14 
Analyses were performed using Stata version 14 (StataCorp. College Station, Texas, USA), and SAS 15 
version 9.4 (SAS Institute, North Carolina, USA).  16 
 17 
 18 
RESULTS 19 
The present analysis included 2707 patients, of which 963 (36%) had diabetes. Of those with 20 
diabetes, 651 (24% of all participants; 68% of those with diabetes) did not have microvascular 21 
complications reported whereas 312 (12%; 32%) did. Median follow-up was 2.1 years among 22 
patients without diabetes, 2.0 years among patients with diabetes but no microvascular 23 
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complications and 1.6 years among patients with diabetes and microvascular complications. Among 1 
the 312 patients with microvascular complications, 107 (34%) were reported to have nephropathy, 2 
135 (43%) retinopathy, and 216 (69%) neuropathy. In terms of number of microvascular 3 
complications 197 (63%) had one, 85 (27%) had two and 29 (9%) had all three microvascular 4 
complications. 5 
Baseline characteristics: As shown in Table 1, individuals without diabetes were, on average, 6 
younger (mean age 59.6 years) than both those with diabetes and no complications (61.2 years) and 7 
diabetes with microvascular complications (61.8 years). Patients without diabetes had shortest 8 
median duration of heart failure (36, 36 and 53 months, respectively) or to be in NYHA class IV 9 
(7%, 9% and 12%, respectively); patients without diabetes had the best, and those with diabetes and 10 
microvascular complications the worst, disease-related quality of life, evaluated using the 11 
Minnesota Living with Heart Failure score (51, 54 and 60 points, respectively). Compared to those 12 
without diabetes, kidney function was most markedly reduced (eGFR 70, 70 and 54 ml/min/1.73m2, 13 
respectively) and plasma norepinephrine was lowest (537, 481 and 467 pg/ml, respectively) in 14 
patients with microvascular complications. Patients without diabetes were least likely, and those 15 
with microvascular complications most likely, to have an ischemic etiology (54%, 65% and 72%, 16 
respectively) and history of hypertension (53%, 68% and 73%, respectively). Among patients with 17 
diabetes, those with microvascular complications were more likely to be treated with insulin (68% 18 
versus 28% in patients with diabetes but without microvascular complications). 19 
Clinical outcomes according to microvascular complication status: The rates of the composite 20 
outcome of cardiovascular death or heart failure hospitalization, each of its components and death 21 
from any cause were lowest in patients without diabetes, intermediate in individuals with diabetes 22 
but without microvascular complications and highest in those with diabetes and microvascular 23 
complications (Table 2 and Figure 1).  24 
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In adjusted analyses, compared to participants without diabetes, the risk of the composite outcome 1 
was significantly higher in those with diabetes and without microvascular complications (HR 1.18 2 
[1.03-1.35]), as well as in individuals with diabetes and complications (HR 1.44 [1.22-1.70]). 3 
Quantitatively similar trends were apparent for the components of this composite outcome and for 4 
death from any cause, although the higher risks were only statistically significant in patients with 5 
diabetes and microvascular complications and not in diabetes patients without microvascular 6 
complications (Table 2 and Figure 1). Compared to those without diabetes, the adjusted risk of 7 
these adverse clinical outcomes was around 15-20% higher in patients with diabetes and no 8 
microvascular complications and approximately 35-50% higher in patients with diabetes and 9 
microvascular complications. A direct comparison of outcomes in diabetes patients with and 10 
without microvascular complications is listed in the Appendix (Supplementary Table 1). Analyses 11 
excluding African-American patients (n=627), yielded results similar to those of the primary 12 
analyses (Supplementary Table 2, Appendix).  13 
 14 
Clinical outcomes according to individual type of microvascular complication and multiple 15 
microvascular complications: The rates of the composite outcome, its components and all-cause 16 
mortality for patients with one or more than one microvascular complication, as well as individual 17 
types of microvascular complication, are shown in Supplementary Table 3. The rates of all 18 
outcomes were higher in patients with more than one microvascular complication compared to 19 
those with a single microvascular complication. Compared to patients with no diabetes, the adjusted 20 
risk of each outcome was approximately 30% higher in those with one complication and 21 
approximately 60-70% higher in individuals with more than one microvascular complication. The 22 
elevation in risk for fatal outcomes was similar for each individual type of microvascular 23 
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complication, whereas the risk of heart failure hospitalization was numerically higher for 1 
nephropathy than for retinopathy or neuropathy (Supplementary Table 3). 2 
Clinical outcomes according to microvascular and macrovascular complication status: When 3 
diabetes patients were further stratified according to the absence or presence of both microvascular 4 
and macrovascular complications, those with neither type of complication were at lowest risk and 5 
those with both types of complications at highest risk, although the number of patients with 6 
microvascular complications but without macrovascular disease was small (Supplementary Table 4 7 
and 5; Supplementary Figure 1a and 1b). In adjusted analyses, the greater risk was conferred by 8 
microvascular complications, compared with macrovascular disease. Compared to patients without 9 
diabetes, diabetes patients without micro- or macrovascular complications had similar risk of the 10 
primary endpoint (p=0.212) whereas diabetes patients with micro and/or macrovascular 11 
complications had a higher risk (all p-values <0.05)   12 
 13 
DISCUSSION 14 
The frequency and significance of microvascular complications in patients with HFrEF and diabetes 15 
is unknown. We found that of the 964 participants in BEST with diabetes, 313 patients (32%) had 16 
microvascular complications. The commonest microvascular complication among these individuals 17 
was neuropathy (69% of those with complications), followed by retinopathy (43%) and 18 
nephropathy (34%) and 37% had more than one microvascular complication. In analyses adjusted 19 
for other predictors of adverse outcomes, patients with diabetes but without microvascular 20 
complications were approximately 20% more likely than patients without diabetes to experience a 21 
major fatal or non-fatal cardiovascular event. Those with microvascular complications were around 22 
40% more likely than patients without diabetes to experience one of these events. Each type of 23 
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microvascular complication was associated with a higher risk of adverse outcomes and the risk was 1 
greatest in patients with multiple microvascular complications. 2 
The prevalence of microvascular complications in patients with type 2 diabetes is related to 3 
adequacy of glycemic control and duration of diabetes.5,11 The reported prevalence also depends on 4 
the patient evaluation employed, with a higher frequency of these microvascular complications 5 
identified in studies using high-fidelity investigations such as retinal angiography and sophisticated 6 
testing of peripheral and autonomic nervous function.5  7 
Prevalence of diabetes with microvascular complications in HFrEF vs. other CV disease: We 8 
have been unable to find any other report of the rate of microvascular complications in patients with 9 
HFrEF and diabetes. Although there was no major difference in age between the three subgroups of 10 
patients examined, patients with diabetes and complications were much more likely to be treated 11 
with insulin than those without complications, implying a longer duration of diabetes in the former 12 
group. This group (patients with diabetes and complications) also had longer duration heart failure 13 
than either patients with diabetes and no complications or those without diabetes. This in turn 14 
suggests that diabetes leads to onset of heart failure at an earlier age in patients with diabetes who 15 
develop microvascular complications. However, the frequency of these complications in the present 16 
study is consistent with other studies using similar reporting methods in patients with 17 
cardiovascular disease in approximately the same age range. For example, in the Canagliflozin 18 
Cardiovascular Assessment Study (CANVAS), 31% participants had neuropathy, 21% retinopathy 19 
and 18% nephropathy (22%, 14% and 11%, respectively, in the present study).12 In the 20 
PROspective pioglitAzone Clinical Trial In macroVascular Events trial (PROACTIVE), 42% of 21 
patients with type 2 diabetes and macrovascular disease were reported to have microvascular 22 
complications (no breakdown of type of microvascular complication was described).13  23 
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Microvascular complications in diabetes and HFpEF: Of more interest is a recent study in 1 
patients with heart failure and preserved ejection fraction (HFpEF). In the Treatment of Preserved 2 
Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 32% of patients 3 
were reported to have a microvascular complication (neuropathy in 21%, retinopathy in 15% and 4 
nephropathy in 11% of participants with diabetes).14 Patients in TOPCAT were on average 5 
approximately 7 years older than participants in the present study and a similar proportion in the 6 
two trials were treated with insulin (38% in TOPCAT versus 41% in BEST). The similar rate of 7 
these complications in TOPCAT is perhaps surprising given the older age of the TOPCAT patients 8 
and the emerging view that microvascular disease may be a feature of HFpEF itself and play an 9 
important role in the pathophysiology of this syndrome.15 10 
Risk according to type of microvascular complication: In patients with type 2 diabetes in general, 11 
higher HbA1c values is associated with greater risk of microvascular complications which in turn 12 
are associated with future cardiovascular risk.4,16,17 We found the same to be true in HFrEF although 13 
the absolute rate of cardiovascular death or heart failure hospitalization in patients with at least one 14 
microvascular complication was extraordinarily high at 45 per 100 person-years of follow-up 15 
(compared with 34 and 29 in those with diabetes and no microvascular complications and 16 
participants without diabetes, respectively). The rate increased to 60 per 100-person years of 17 
follow-up in those with more than one complication i.e. more than one in two of these patients 18 
suffered a major adverse heart failure-related event annually. While each individual type of 19 
complication was associated with a higher risk (compared with no complication), there was a 20 
suggestion that neuropathy and retinopathy conferred a greater risk of death whereas nephropathy 21 
was more closely associated with risk of heart failure hospitalization. If true, the relationship 22 
between nephropathy and heart failure hospitalization is plausible in that renal dysfunction is likely 23 
to lead to or accentuate the sodium and water retention that characterises worsening of heart failure. 24 
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Similarly, neuropathy, including autonomic neuropathy, can be plausibly linked to cardiovascular 1 
death.5 Indeed, reduced iodine-123 meta-iodobenzylguanidine uptake, indicative of cardiac 2 
sympathetic dysregulation, has been demonstrated in patients with diabetes and in patients with 3 
HFrEF and diabetes is independently predictive of progression of heart failure.18 Interestingly, in 4 
the present study, we found that diabetes patients with microvascular complications had lower 5 
plasma norepinephrine levels than diabetes patients without microvascular complications and 6 
patients without diabetes. Why diabetic retinopathy seems to be more closely associated with the 7 
risk of death compared with hospital admission is less obvious. This complication is thought to 8 
indicate the presence of widespread end-organ microcirculatory damage and investigator-reported 9 
retinopathy likely reflects the most advanced stage of this problem.11  Consequently, retinopathy 10 
may simply be a marker of more severe microvascular disease. Alternatively, the development of 11 
retinopathy may reflect additional pathophysiologic processes which are also generally more 12 
harmful in heart failure. Mechanisms of this type that have been implicated in the development of 13 
retinopathy include inflammation, oxidative stress and persistent activation of the renin-angiotensin 14 
system.11 In addition, microvascular disease may particularly affect the myocardium in patients with 15 
diabetes which is clearly of greatest danger in patients with already dysfunctional myocardium.19 16 
Due to the suggestion of less benefit of drug therapy and higher rates of diabetic complications in 17 
African-Americans, we repeated analyses without these patients with similar results.20,21 Another 18 
potential risk factor for developing HF in diabetes patients microvascular complications is their 19 
presumed more severe diabetes and for this reason intensified glucose-lowering therapy, where 20 
some drug classes including pioglitazones have been linked to an increased risk of HF.22 21 
Clinical Implications: What are the clinical implications of these findings? Firstly, the diagnosis of 22 
microvascular complications identifies patients at extremely high risk of adverse outcomes and 23 
physicians should check that disease modifying therapy for heart failure has been maximized and 24 
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diabetes treatment likewise optimized. Second, and perhaps more importantly, prevention of 1 
microvascular complications seems to be highly desirable, given the prognostic implications of their 2 
development, although this association between microvascular complications and worse outcomes 3 
could be an epiphenomenon rather than a modifiable risk factor. Clearly, prevention of 4 
microvascular complications is a recognized goal of diabetes therapy, although perhaps not always 5 
considered a priority by cardiologists.23,24 Our findings suggest that cardiologists should also have 6 
prevention of these complications as a treatment goal, although it has to be acknowledged that the 7 
cardiovascular safety of all diabetes drugs in patients with HFrEF has never been established. 8 
 9 
Limitations: As with any report of this type, our study has a number of limitations. Glycated 10 
hemoglobin levels were not measured. Similarly, duration of diabetes was not documented. 11 
Microvascular complications were reported by investigators and not specifically sought using 12 
disease-specific questionnaires or specialist testing; both of the latter may have yielded a higher 13 
frequency of these complications. For patients without diabetes no information on microvascular 14 
complications were available. Finally, it is possible that more contemporary HF treatment with a 15 
more effective beta-blocker, MRA and angiotensin-receptor neprilysin inhibitor, as well as use of 16 
cardiac devices could improve prognosis in patients with HF and diabetes with microvascular 17 
complications. 18 
 19 
In summary, we found that about a third of HFrEF patients with diabetes in the BEST trial had 20 
microvascular complications and 37% of these had multiple complications. The commonest 21 
complication was neuropathy. Patients with diabetes and microvascular complications were around 22 
40% more likely than a patient without diabetes to experience a major adverse cardiovascular event 23 
13 
 
(which was about twice the incremental risk associated with diabetes and no complications). Each 1 
type of microvascular complication was associated with a higher risk of adverse outcomes and the 2 
risk was greatest in patients with multiple complications. The resultant absolute rate of adverse 3 
cardiovascular outcomes in HFrEF patients with diabetes and multiple microvascular complications 4 
was extraordinarily high (rate of cardiovascular death or heart failure hospitalization 60 per 100 5 
person-years of follow-up). Cardiologists need to work in tandem with endocrinologists and 6 
primary care practitioners to prevent microvascular complications in their HFrEF patients with 7 
diabetes. The presence of microvascular complications should be checked for regularly in order to 8 
identify patients at particularly high risk and maximize surveillance and therapy as appropriate. 9 
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Table 1: Baseline characteristics according to diabetes status with or without microvascular 
complications 
  Diabetes  
  Microvascular complications  
Patients, no (%) 
No diabetes 
1743 (64%) 
No 
651 (24%) 
Yes  
313 (12%) p-value 
Characteristics     
Age, mean 59.6±13.3 61.2±10.7 61.8±9.9 0.0012 
Male, n (%) 1364 (78%) 508 (78%) 242 (77%) 0.933 
Caucasian, n (%) 1253 (72%) 508 (78%) 242 (77%) 0.0611 
HF duration, months 36 (11, 70) 36 (13, 69) 53 (20, 84) <0.001 
NYHA class, n (%)    0.0094 
III 1616 (93%) 590 (91%) 275 (88%)  
IV 127 (7%) 61 (9%) 38 (12%)  
LVEF 22.7±7.4 23.3±7.0 23.7±7.2 <0.0001 
RVEF 35.1±31.5 34.2±13.9 34.8±12.8 0.4621 
Left bundle branch block 448 (26%) 150 (23%) 81 (26%) 0.3857 
Right bundle branch block 119 (7%) 39 (6%) 20 (6%) 0.7559 
QRS-duration, ms 130±36  124±34 127±31 0.0055 
LV hypertrophy 405 (23%) 145 (22%) 66 (21%) 0.6666 
Heart rate, bpm 81±13 84±13 83±12 <0.0001 
SBP, mmHg 116±17 120±19 120±18 <0.0001 
MLHF score 51 (32, 69) 54 (32, 74) 60 (41, 78) <0.0001 
BMI, Kg/m2 27.3±5.7 29.4±6.2 29.1±5.6 <0.0001 
eGFR, ml/min/1.73m2 70 (55, 85) 70 (54, 87) 54 (41, 71) <0.0001 
Plasma norepinephrine, pg/mL 537±351 481±344 467±293 0.0004 
Plasma glucose, mmol/L 5.70±1.78 10.22±4.99 11.57±5.57 <0.0001 
Medical history, n (%)     
Ischemic etiology 942 (54%) 421 (65%) 224 (72%) <0.0001 
Hypertension 923 (53%) 444 (68%) 228 (73%) <0.0001 
Peripheral artery disease 204 (12%) 112 (17%) 125 (40%) <0.001 
Atrial fibrillation 436 (25%) 143 (22%) 74 (24%) 0.2937 
Thromboembolic disease 311 (18%) 118 (18%) 59 (19%) 0.9104 
ICD, n (%) 72 (4%) 13 (2%) 5 (2%) 0.0067 
Pacemaker, n (%) 154 (9%) 51 (8%) 26 (8%) 0.729 
Medication, n (%)   
Loop diuretic  1606 (92%) 622 (96%) 305 (97%) <0.0001 
Digoxin 1613 (93%) 595 (91%) 291 (93%) 0.5804 
ACE-I/ARB 1690 (97%) 627 (96%) 300 (96%) 0.5038 
MRA  45 (3%) 31 (5%) 16 (5%) 0.0067 
Oral antidiabetic agent 0 (0%) 386 (59%) 126 (40%) <0.0001 
Insulin 0 (0%) 185 (28%) 213 (68%) <0.0001 
Diet only 0 (0%) 110 (17%) 7 (2%) <0.0001 
Diabetic retinopathy 0 (0%) 0 (0%) 135 (43%) <0.0001 
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Diabetic neuropathy 0 (0%) 0 (0%) 216 (69%) <0.0001 
Diabetic nephropathy 0 (0%) 0 (0%) 107 (34%) <0.0001 
ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; HF = heart failure, ARB = angiotensin 
receptor blocker; BMI = body mass index; eGFR = estimated glomerular filtration rate; HF = Heart Failure; ICD = 
implantable cardioverter-defibrillator; LV = left ventricular; LVEF = left ventricular ejection fraction; MLHF = 
Minnesota Living with Heart Failure questionnaire; MRA = mineralocorticoid-receptor antagonist; NYHA = New York 
Heart Association; RVEF = right ventricular ejection fraction SBP = systolic blood pressure   
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Table 2:  Risk of various endpoints according to diabetes status with or without 
microvascular complications at baseline 
  
No. 
events 
Crude rate               
per 100py  
Unadjusted HR 
P 
Adjusted* HR 
P 
(95% CI) (95% CI) 
Primary comp. (CV death 
or HFH)        
No diabetes 817 28.7 1.00 (ref.) 
 
1.00 (ref.) 
 
Diabetes + no complications 340 33.5 1.15 (1.02-1.31) 0.028 1.18 (1.03-1.35) 0.016 
Diabetes + complications 197 50.0 1.64 (1.40-1.92) <0.001 1.44 (1.22-1.70) 
<0.00
1 
       
CV death 
      
No diabetes 429 12.0 1.00 (ref.) 
 
1.00 (ref.) 
 
Diabetes + no complications 182 14.0 1.17 (0.98-1.39) 0.080 1.20 (1.00-1.44) 0.054 
Diabetes + complications 119 21.2 1.78 (1.45-2.18) <0.001 1.49 (1.20-1.85) 
<0.00
1 
       
HF hospitalization 
      
No diabetes 639 22.4 1.00 (ref.) 
 
1.00 (ref.) 
 
Diabetes + no complications 260 25.6 1.12 (0.97-1.30) 0.112 1.15 (0.99-1.34) 0.077 
Diabetes + complications 145 36.8 1.52 (1.27-1.83) <0.001 1.35 (1.11-1.63) 0.002 
       
All-cause mortality 
      
No diabetes 512 14.3 1.00 (ref.) 
 
1.00 (ref.) 
 
Diabetes + no complications 214 16.4 1.15 (0.98-1.35) 0.080 1.20 (1.01-1.42) 0.035 
Diabetes + complications 133 23.7 1.68 (1.38-2.03) <0.001 1.42 (1.16-1.74) 
<0.00
1 
*adjusted for age, sex, race, systolic blood pressure, heart rate, BMI, NYHA, LVEF, eGFR, study treatment, ischemic 
etiology, hx hypertension, hx AF, ICD, pacemaker.  
CI = confidence interval; CV = cardiovascular; HFH = heart failure hospitalization; HR = hazard ratio; PY = person 
years; other abbreviations as footnote to Table 1. 
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Figure 1a: Cumulative incidence of cardiovascular death or heart failure hospitalization 
 
 
Figure 1b: Cumulative incidence of all cause death   
 
 
